For decades, pancreatic cancer has been almost impossible to treat. A new drug targeting the mutation driving 90% of cases may finally be changing that — and patients won’t have to wait long to access it.

Scientists have spent decades trying to drug the KRAS mutation — often called “undruggable.” A new compound called daraxonrasib may have finally cracked it. (Photo placeholder — replace with licensed image)

Survival improvement ~2x vs. prior standard of care

Reduction in death risk 60% Phase 3 trial results

Pancreatic cancers with KRAS mutation 90%+ the target this drug hits

Expected FDA approval 2026 late this year or early 2027

If you’ve ever known someone with pancreatic cancer — and statistically, many of us have — you know the conversation that follows a diagnosis tends to move very quickly from “treatment options” to “getting your affairs in order.” The five-year survival rate has hovered around 12% for years. It is, bluntly, one of the cancers doctors dread telling patients they have.